65 results about "Preclinical research" patented technology

The invention discloses gallium ion-quercetin coordination nanoparticles (GQNPs) as well as a preparation method and application thereof, specifically, quercetin, gallium nitrate hydrate and polyvinylpyrrolidone are respectively dissolved in an absolute methanol solution to prepare a quercetin solution, a gallium nitrate hydrate solution and a polyvinylpyrrolidone solution; secondly, fully mixing the quercetin solution and the polyvinylpyrrolidone solution, dropwise adding the gallium nitrate hydrate solution, and rapidly changing the color of the mixed solution from faint yellow to orange yellow in the dropwise adding process; and finally, dialyzing the orange-yellow mixed solution to remove excessive gallium ions and polyvinylpyrrolidone, thereby finally obtaining the GQNPs. The prepared GQNPs and deferiprone show excellent treatment effects on cell and living body levels, are expected to be applied to treatment of Parkinson's disease through multi-dimensional anti-ferroptosis, do not show obvious toxic and side effects in the embodiment, and are expected to be applied to further preclinical research.

The invention discloses a tumor angiogenesis detection and analysis method based on multi-modal image fusion, and relates to the technical field of medical imaging, and the method comprises the steps: collecting multi-modal image data of a target tumor; performing feature extraction on the acquired multi-modal image data according to a neural network model; fusing the extracted features through a fusion network to obtain a comprehensive feature vector; analyzing the tumor angiogenesis state according to the comprehensive feature vector to obtain an analysis result; according to the analysis result, the angiogenesis state of the tumor is evaluated, and a report is generated. More comprehensive tumor angiogenesis information can be provided, and the accuracy of detection and analysis is improved. Through multi-modal image data fusion, the in-vivo tumor microenvironment can be simulated more truly. The method can be used as a preclinical research platform of anti-tumor and anti-tumor angiogenesis drugs, and provides support for drug screening and evaluation.

The present invention discloses a fluorescent probe for detecting Aβ aggregates, its preparation method and applications. Specifically, the structure of the probe is shown in Formula I. The Aβ aggregate probe provided by the present invention has various uses, can be used for the recognition and detection of Aβ aggregates in vitro and in biological tissue sections, is used for β-amyloid protein imaging in biological tissues with high sensitivity, and has wide applications in the early diagnosis of Alzheimer's disease, preclinical research and development of anti-AD drugs, and the revelation of pathological mechanisms.

The invention belongs to the technical field of neurobiology and pain mechanism research, and discloses a full-automatic pain sense measuring system based on artificial intelligence integrated vital sign monitoring, which is integrated with multi-mode biological signal acquisition equipment, can synchronously record pain sense behaviors and physiological data (such as heart rate, respiratory rate, body temperature, excretion and the like) of experimental animals, and can be used for measuring the pain sense of the experimental animals. And the acquired data is analyzed and processed in real time by using an artificial intelligence algorithm to generate quantitative pain assessment indexes. Compared with a traditional pain assessment method depending on subjective observation, the system has the advantages that the efficiency and accuracy of data acquisition and analysis are remarkably improved, the human deviation can be reduced, and the assessment error rate is reduced to 5% or below. The method is particularly suitable for research of complex pain models and high-throughput drug screening, the preclinical research and development period can be remarkably shortened by 20%-30%, and the research and development cost is reduced. The invention has obvious market demand and economic benefit, and provides important technical support for the field of pain research.

The present disclosure relates to Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), an autosomal dominantly inherited neurodegenerative disorder that is caused by an over-repetition of the polyglutamine-codifying region in the ataxin-3 (ATX7V3) gene. Expanded ATXN3 is prone to aggregate and disturbs diverse cellular systems, ultimately leading to cell dysfunction and death in specific neuronal populations. To date, no treatment able to reverse or stall MJD / SCA3 progression has been developed. Strategies based on the suppression of the deleterious gene products have demonstrated promising results in pre-clinical studies. Nonetheless, these strategies do not target the root cause of the disease, producing an incomplete and / or transient therapeutic effect in target cells or tissues. Recently, gene-based therapeutics, including the bacterial clustered regularly interspaced short palindromic repeat (CRISPR) systems for gene edition, have been successfully used to permanently inactivate and correct disease-related genes, holding promise for the development of a definitive cure for inherited diseases.

The invention relates to a touch fluid neuron specific tracing imaging agent, a preparation method and application, and belongs to the technical field of nuclear medicine imaging, the tracing imaging agent is composed of a nerve tracer agent horseradish peroxidase (HRP), zirconium-89 isotope chelated by deferoxamine and a pharmaceutically acceptable carrier, the effective tracking window of the tracer agent is prolonged to 120 hours, and the effective tracking window of the tracer agent is prolonged to 120 hours. The multi-stage synaptic transfer period of the fluid touching neuron can be completely covered; the spatial resolution is improved by 5-8 times compared with that of traditional FDG-PET, and a fluid touching neuron cluster can be accurately presented; the in-vitro serum stability is excellent, the radiochemical purity is still larger than or equal to 80.5% within 120 hours, PET / MRI bimodal imaging can be adapted, drug administration is conducted through lateral ventricle minimally invasive injection, the probe is suitable for various animal models such as mice, rats and non-human primates, in-vivo dynamic tracing of sympathetic fluid neuron trans-synapses can be achieved on the premise that no tissue damage exists, and the probe has a good application prospect. And a key technical tool is provided for neural circuit analysis, neuroscience basic research and preclinical research of neurodegenerative diseases.

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The present invention discloses a toxicity prediction model for predicting agranulocytosis induced by non-chemotherapeutic drugs. The toxicity prediction model uses the best molecular descriptor combination of the drug to be tested as input information, and inputs it into the integrated model of the trained BalancedBaggingClassifier combined with the gradient boosting decision tree of the base classifier, thereby obtaining the toxicity prediction result of the drug to be tested. The toxicity prediction model can accurately predict the toxicity of agranulocytosis induced by non-chemotherapeutic drugs, reduce the risk of adverse reactions for agranulocytosis in new drug research and development, reduce research and development costs, and accelerate the research and development process; and the toxicity prediction model can evaluate the risk of agranulocytosis caused by existing non-chemotherapeutic drugs, newly listed unknown adverse reaction drugs or preclinical research / clinical research compounds, provide medication warnings for clinicians, help improve patient medication safety, and improve medical quality and patient quality of life.

The invention relates to the technical field of medicines, in particular to application of aspiramycin and / or imiquimod in preparation of a medicine for treating VACV. Aspiramycin and imiquimod which are screened from medicines on the market have antiviral activity, and experimental data show that the Aspiramycin and the imiquimod have anti-VACV medicine activity. Aspiramycin and imiquimod (especially combined application) are used for preparing the medicine for treating VACV, so that the time and cost of preclinical research can be greatly reduced. As the action mechanism of the pox viruses is not unique to the VACV, the combined strategy has the potential to be expanded to infection treatment of other pox viruses (such as monkey pox virus MPXV) and even other DNA (Deoxyribose Nucleic Acid) viruses.

The invention provides a preparation method of a polymer nanorod with a controllable and adjustable length-diameter ratio. The invention further provides a preparation method of the anti-tumor nano-drug, the anti-tumor nano-drug is prepared by the preparation method of the polymer nano-rod with the controllable and adjustable length-diameter ratio, and the paclitaxel nano-drug is prepared by the method. The three-step method adopted by the invention is based on a traditional emulsification method, special instruments and equipment are not needed, large-scale production is easy to realize, and the batch yield is relatively high; the preparation conditions are mild, and the drug activity can be effectively protected; the method is low in energy consumption, economical and efficient. According to the method, the length-diameter ratio of the nanorod can be controllably adjusted on the basis of not changing the raw material composition of the nanorod, the consistency of other parameters in the subsequent biological behavior research is favorably kept, the influence of mixed factors is reduced, and the reliability and repeatability of the research can be improved. Besides, when the length-diameter ratio of the nano-carrier is adjusted, only the process of heating fracture in the last step needs to be changed, so that the cost can be greatly saved, customized production is facilitated, or preclinical simple preparation is realized.

The invention discloses a traditional Chinese medicine composition for resisting ovarian cancer and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 9 parts of dandelion, 9 parts of cyrtomium fortunei, 9 parts of sanguisorba officinalis, 9 parts of pericarpium citri reticulatae, 9 parts of honeysuckle, 9 parts of ginseng, 9 parts of cirsium japonicum, 9 parts of herba cepbalanoplosis segeti, 15 parts of longan aril, 15 parts of radix rehmanniae, 15 parts of eucommia ulmoides and 6 parts of pseudo-ginseng. The invention not only proves the phenotypic effects of the tonifying and cancer eliminating decoction for inhibiting the proliferation and migration of ovarian cancer cells and inducing apoptosis, but also finds that the effect of the tonifying and cancer eliminating decoction is closely related to the activation of inhibiting a PI3K-AKT signal channel for the first time, the scientific connotation of the tonifying and cancer eliminating decoction is clarified from the molecular level, and an important preclinical research foundation is laid for developing the tonifying and cancer eliminating decoction into a modern new traditional Chinese medicine for resisting ovarian cancer.

The invention relates to cellulose derivative matrigel and application thereof in a tumor CDX or PDX model, the cellulose derivative matrigel is a ready-to-use hydrogel free of animal-derived components, can be used for constructing an efficient and stable tumor CDX or PDX model, is simple to operate, has high similarity with clinical tumors, and can be used for preparing the tumor CDX or PDX model. And a solution is provided for clinical curative effect prediction and preclinical research.

The invention belongs to the technical field of medicines, and particularly relates to a novel method for relieving toxic and side effects of bevacizumab. Based on preclinical research, the combination of glutathione and bevacizumab relieves toxic and side effects on immune cells when bevacizumab is independently used. Experimental data comparison shows that compared with bevacizumab single drug treatment, the combined glutathione can significantly reduce the inhibition effect on immune cell activity, so that the cell proliferation activity is repaired, and meanwhile, the disordered cell cycle and the abnormally expressed cell factor level tend to be normalized. The invention provides a novel treatment scheme and thought for targeted treatment of tumor patients with the VEGF monoclonal antibody bevacizumab, is also beneficial to research on the toxic action mechanism of drugs and optimization of the treatment scheme, and has important potential clinical experimental research value.

The application discloses a kind of fast high signal-to-noise ratio CEST quantification parameter map calculation methods based on K-means clustering, method includes: according to the pixel number and standard deviation of CEST-MRI image Setting clustering termination condition;K-means clustering is carried out to the target to be clustered, and the average Z spectrum of each class is fitted respectively;For the class that does not meet the condition, the class is taken as the target to be clustered, and the fitting parameter of the average Z spectrum of the class is taken as the initial value of fitting after next clustering, turn to clustering step;For the class that meets, the fitting value of the class is taken as the quantification signal output of all pixels in the class, and when all classes meet the clustering termination condition, the fitting value of all classes is output based on class fitting Quantification map according to the fitting value of all classes.The method can improve the signal-to-noise ratio and fitting accuracy of CEST-MRI quantification map and significantly reduce the calculation time, which is beneficial to the promotion and application in preclinical research and clinical practice.

The invention belongs to the field of biological medicine, and particularly relates to a Bama pig model for preclinical research of a weight-reducing medicine COST and application of the Bama pig model. Healthy Bama pigs are firstly adaptively fed with common feed and then fed with high-fat feed for molding, and obesity-related indexes of the Bama pigs are detected in a fixed period of time every week; the high-fat feed comprises common feed, beef tallow, margarine, cane sugar, casein, laboratory animal premix, microcrystalline cellulose, calcium bicarbonate, gypenosides, mint leaves, maslinic acid, ursolic acid, bighead atractylodes rhizome and nutmeg. According to the invention, the Bama pig model with stable phenotype can be rapidly constructed, a reliable model is provided for preclinical research of new drugs for treating obesity, and guarantee is provided for research of obesity mechanisms and screening, development and mechanism research of the new drugs for treating obesity.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

This invention discloses a method for constructing lung organoids with spontaneous vascularization and branching morphology. By optimizing the culture protocol and progressively inducing directional mesoderm, vascularized foregut endoderm, vascularized lung bud organoids, and vascularized lung organoids, lung organoids with both vascularization and branching morphology are successfully cultured, thus more realistically simulating the structural characteristics of the human lung. This invention has significant advantages: First, it can effectively induce the formation of vascularization and branching structures in lung organoids, overcoming the shortcomings of traditional lung organoids that lack vascularization and branching structures; second, by adjusting the culture method in the early stages, the uniformity of the lung organoids is significantly improved, enhancing the reliability and reproducibility of experimental results. This invention provides a more precise and efficient experimental platform for preclinical studies such as lung disease research, drug screening, and toxicology testing, and has significant application value.

Described herein are methods of treating muscular dystrophy comprising administering a recombinant AAV (rAAV) scAAVrh74.MHCK7.hSGCB vector, methods of expressing beta-sarcoglycan gene in a patient, pharmaceutical compositions comprising the rAAV, and methods of generating the rAAV. The disclosed methods reduce fibrosis and improve muscle function by restoring B-sarcoglycan expression in muscle tissues. The disclosure further provides preclinical studies in animal models, and a clinical trial involving systemic delivery of the vector to patients, which shows significant improvements in muscle pathology, force production, and overall activity in treated subjects.

Provided is a universal preclinical bio-distribution detection kit for NK cell therapy products. The present invention further relates to specific use of a gene sequence set forth in SEQ ID No. 1 in distinguishing a human NK cell gene from a non-human animal gene. By means of providing a specific DNA sequence, a DNA sequence derived from the human NK cell can be specifically distinguished from a DNA sequence derived from the non-human animal gene, and based on the specific DNA sequence, a qPCR system for distinguishing the human NK cell gene from the non-human animal gene is constructed, providing a primer pair and a probe set for NK cells and derivative cell therapy products thereof. In addition, a universal preclinical bio-distribution detection kit for the NK cell therapy products is successfully designed, thereby providing convenience for the preclinical research on the NK cells and derivative cell therapy products thereof.

The invention relates to the technical field of biomedicine, and discloses an experimental method for treating osteomyelitis by using human umbilical cord mesenchymal stem cells. The method aims at solving the problems that an existing osteomyelitis experimental model is disjointed from clinical pathological characteristics, the activity loss of mesenchymal stem cells in an infection environment is large, a combined intervention scheme lacks pathological suitability, and an evaluation system is single. The method comprises the following steps: firstly, constructing a clinical adaptive model by combining pathogenic bacterium injection with immunosuppression and ischemia induction, then carrying out anti-oxidation and targeted colonization double pretreatment on MSC, then implementing stepped combined intervention according to the requirements of acute-stage bacterium control and chronic-stage repair, and comprehensively evaluating through infection control, immune balance and bone repair multi-dimensional indexes, so as to obtain a bone repair model. The constructed model is closer to clinical pathological characteristics, the MSC activity and colonization ability are stable, the intervention scheme collaboration is high, the evaluation result is comprehensive and reliable, a standardized tool can be provided for preclinical research of osteomyelitis treatment schemes, and the conversion guidance value of the experimental result is improved.

Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefits and value of cannabinoids, clinical acceptance has been limited due to CNS side effects at systemic analgesic doses and the fear of misuse potential. What is needed are novel cannabinoid-acting compositions and methods for treating pain. The present disclosure relates to compositions targeting cannabinoid receptors and uses thereof for treating, preventing, and / or mitigating pain.

This invention discloses the application of total flavonoids from sea buckthorn leaves in the preparation of drugs for treating ulcerative colitis, relating to the pharmaceutical field. Animal experiments of this invention have demonstrated that total flavonoids from sea buckthorn leaves can effectively alleviate clinical symptoms and pathological damage of ulcerative colitis; improve intestinal barrier damage in mice with ulcerative colitis; improve the inflammatory response in mice with ulcerative colitis; improve the decreased secretion of short-chain fatty acids in mice with ulcerative colitis; and regulate the abundance and structure of intestinal flora in mice with ulcerative colitis. It shows promise for developing new anti-ulcerative colitis drugs. Therefore, sea buckthorn leaves can be transformed from waste into a valuable resource, providing solid preclinical research evidence for the subsequent development of special medical foods, health products, or functional teas with sea buckthorn leaf flavonoids as the core component, offering daily nutritional support and disease management for patients with ulcerative colitis.

The invention relates to an animal model for meningitis / ventricitis caused by klebsiella pneumoniae after craniocerebral trauma and a construction method of the animal model. The animal model is obtained through immunosuppression, craniocerebral injury and intracranial infection. According to the invention, craniocerebral trauma and a bacterial infection meningitis / ventricular inflammation model are combined for the first time to simulate the pathological state of a patient suffering from meningitis / ventricular inflammation caused by klebsiella pneumoniae after neurosurgery, and the method can be applied to the physiological and pathological research of the diseases; secondly, the model animal is subjected to sampling after administration, tissue penetrability research can be carried out, the pathological characteristics of a clinical patient can be better fitted, and the change of the medicine at a specific part along with time under different infection states is described according to the sampling of a target part and medicine quantification; and thirdly, the method can be applied to preclinical research of meningitis biomarkers, and provides model support for immunological research of cytokine change and the like after meningitis.

The invention relates to a skin-like chip simulation platform based on a microfluidic technology. The skin-like chip simulation platform sequentially comprises a skin-like layer, a skin-like layer, a cytoplasm matrix simulation layer and an interstitial fluid circulation layer from top to bottom, a hole array is arranged on the imitated skin layer; an interstitial fluid enrichment cavity communicated with the hole array is formed in the simulated cortex, and the interstitial fluid enrichment cavity is provided with an enrichment outlet and an enrichment inlet; an interstitial fluid micro-channel is arranged in the cytoplasm matrix simulation layer, one end of the interstitial fluid micro-channel is communicated to the enrichment inlet, and the other end of the interstitial fluid micro-channel is communicated to the interstitial fluid flowing layer; an interstitial fluid storage cavity is formed in the interstitial fluid circulation layer and is provided with a storage cavity outlet and a storage cavity inlet; the device further comprises an interstitial fluid circulation channel. The skin-like chip simulation platform designed by the invention can accurately simulate the human skin environment, provides a simulation test platform for novel extraction electrode design, parameter optimization and safety evaluation of a counter ion electroosmosis technology, and remarkably reduces the preclinical research risk and cost of new technology development.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

The invention discloses preparation and application of a micromolecular nano modifier for enhancing active targeting. The preparation method comprises the following steps: synthesizing a micromolecular double-target affinity agent GLM; the preparation method comprises the following steps: grafting a micromolecular double-target affinity agent GLM to a side chain of PEG to obtain PEG-GLM; and modifying the PEG-GLM onto the surfaces of the porphyrin-based metal organic framework PCN-224 nano particles, so as to obtain the polyethylene glycol-micromolecule co-modified nano material. According to the invention, a high-affinity micromolecular nano-material GLM aiming at VEGFR (vascular endothelial growth factor receptor) and PDGFR (PDGFR) double targets is synthesized and is grafted to PEG (polyethylene glycol). After the synthesized GLM-PEG is modified on the nano material PCN-224, a cellular uptake experiment and an in-vivo fluorescence imaging experiment jointly verify that the nano material has excellent capability of actively targeting liver cancer from a cellular level and an animal level. The follow-up preclinical research and clinical transformation are expected to be carried out.

The application relates to the technical field of antibodies, in particular to a novel coronavirus Omicron mutant specific antibody and application thereof. The application provides an antibody specifically combined with the novel coronavirus Omicron mutant, the antibody can be used as a specific antibody for antigen detection of the Omicron mutant, is used for identification of a novel coronavirus vaccine designed for the Omicron mutant, and is used for quantitative detection of the content of Spike RBD protein expressed by the vaccine, or is used for quality control of a novel coronavirus vaccine and immunogenicity detection of clinical and preclinical research, or is used as a quality control antibody for detection of protective antibodies in serum after vaccination.

The application belongs to the field of biological medicine, and particularly relates to a Bama pig model for preclinical research of a weight loss drug COST and application. Healthy Bama pigs are first adaptively fed with ordinary feed, and then fed with high-fat feed to model, and the Bama pigs are detected for obesity-related indexes at a fixed time period every week; the high-fat feed comprises ordinary feed, beef tallow, artificial butter, sucrose, casein, experimental animal premix, microcrystalline cellulose, calcium bicarbonate, gypenoside, peppermint leaf, maslinic acid, ursolic acid, atractylodes, nutmeg. The application can quickly construct a Bama pig model with stable phenotype, and provides a reliable model for preclinical research of a new drug for treating obesity, and provides guarantee for research on the mechanism of obesity, screening, development and mechanism research of a new drug for treating obesity and the like.

The invention discloses a human porta hepatis bile duct cancer cell line and application thereof. The human porta hepatis bile duct cancer cell line comprises a human porta hepatis bile duct cancer cell line JXQ-3D-4339R; the human porta hepatis bile duct cancer cell line JXQ-3D-4339R is preserved in the China Center for Type Culture Collection on November 22, 2023, and the preservation number of the human porta hepatis bile duct cancer cell line JXQ-3D-4339R is CCTCC (China Center for Type Culture Collection) NO: C2023368. The human extrahepatic cholangiocarcinoma cell line can be amplified in quantity, can be subcultured in vitro for a long time, has different sensitivities to cis-platinum, gemcitabine and the like, enriches a human extrahepatic cholangiocarcinoma cell bank, and provides a new test material for revealing the occurrence and development mechanism of extrahepatic cholangiocarcinoma and preclinical research of corresponding drug development.